Fig. 2: mTORC1 enhanced U2OS cell proliferation and migration.
From: mTORC1 accelerates osteosarcoma progression via m6A-dependent stabilization of USP7 mRNA
A Immunoblot analysis of WTAP in shCtrl, shRaptor, or shRictor transfected U2OS cells for 48 h. B Immunoblot analysis of Raptor, p-S6, p-S6K, in shCtrl, shRaptor, or shRictor transfected U2OS cells for 48 h. The EdU staining (C) and EdU positive cells (D) in shCtrl or shRaptor transfected U2OS cells for 48 h, scale bar: 50 µm. E, F The migration capacity and migrated cell number in shCtrl or shRaptor transfected U2OS cells for 24 h, scale bar: 50 µm. G The relative cell proliferation in shCtrl or shRaptor transfected U2OS cells for 0-96 h. H Immunoblot analysis of TSC2, p-S6, p-S6K, in WT or ΔTSC2 U2OS cells treated with or without rapamycin (100 nM). The EdU staining (I) and EdU positive cells (J) in WT or ΔTSC2 U2OS cells treated with or without rapamycin (100 nM), scale bar: 50 µm. K The relative cell proliferation in WT or ΔTSC2 U2OS cells treated with or without rapamycin (100 nM) for 0–96 h. L, M The migration capacity and migrated cell number in WT or ΔTSC2 U2OS cells treated with or without rapamycin (100 nM), scale bar: 50 µm. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs control group, ##P < 0.01, ###P < 0.001, ####P < 0.0001 vs ΔTSC2 group.
